Vitamin D Levels in Early Midlife Linked to Reduced Alzheimer's Brain Changes

A long-term study indicates that vitamin D levels during a person's 30s and 40s may influence early brain changes associated with Alzheimer’s disease, appearing years before clinical symptoms manifest.

Dementia affects an estimated 57 million people globally. While prior research has suggested a link between lower vitamin D levels in later life and an increased risk of cognitive impairment, robust evidence has been limited.

A recent study published in Neurology reports an association between higher circulating vitamin D levels in early midlife and lower tau-PET burden in the brain, which is a potential preclinical marker for dementia in adults without current symptoms.

Study Details

Researchers conducted a prospective cohort study involving 793 dementia-free participants from the Framingham Heart Study Generation 3 cohort. This robust group included 369 participants with tau-PET data and 424 with amyloid-PET data.

Participants' vitamin D levels were initially measured at an average age of 39 years, with a mean level of 38 ng/mL. It was observed that 34% of participants had levels below the study-defined threshold of <30 ng/mL, while a smaller proportion (5%) were taking vitamin D supplements.

Brain positron emission tomography (PET) scans, which are gold-standard tools used to detect amyloid and tau deposition, were performed on participants between 2015 and 2023. Notably, the average interval between the initial blood test for vitamin D and the subsequent PET scan was 16 years, allowing for a longitudinal assessment.

Key Findings

The study results indicated a significant association: higher serum vitamin D levels measured in early midlife were associated with reduced global and composite tau deposition as observed on PET scans. Composite tau specifically refers to deposition in the brain regions typically affected first in Alzheimer's disease dementia.

No significant associations were found when considering the study threshold of vitamin D <30 ng/mL, which may be due to the small subgroup size. Importantly, no changes in amyloid deposition were observed in relation to vitamin D levels at any threshold.

The findings remained consistent even after adjusting for various confounding factors, including demographic characteristics, seasonal variations, vascular health, and depressive symptoms. Excluding participants who used vitamin D supplements did not alter the results. Furthermore, the APOE ε4 genotype, a known genetic risk factor for amyloid and tau deposition, showed no interaction with vitamin D levels regarding either tau or amyloid deposition.

Preliminary analyses suggested a potential dose-response relationship: the highest quintile of vitamin D concentration was associated with a suggested reduction in tau deposition in early-affected brain regions compared to the lower four quintiles. Exploratory post hoc findings using deciles also indicated that the top decile was associated with lower global and composite tau burden.

These observations align with preclinical studies that suggest vitamin D may play a role in modulating tau burden in the brain.

How Vitamin D May Affect the Brain

Vitamin D receptors and the enzyme responsible for converting vitamin D into its active form are widely distributed in critical brain areas like the hippocampus, as well as in immune cells.

Vitamin D is understood to influence neuronal cell metabolism, enhance immune cell responses, and decrease the production of inflammatory cytokines. It is also crucial for the expression of primary antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, thereby contributing to systemic anti-inflammatory capacity.

Vitamin D deficiency can intensify neuroinflammation and diminish antioxidant defenses. This can lead to increased kinase enzyme activity, which in turn enhances tau phosphorylation at critical sites. The active form of vitamin D, calcitriol, may help restore neurotrophic factor signaling and normalize tau phosphorylation activity, potentially preventing tau accumulation.

Study Strengths and Limitations

Strengths

The study is notable for its size within this field, its use of longitudinal data, and the incorporation of gold-standard neuroimaging markers for preclinical dementia. The relatively young baseline age of participants allowed for the investigation of a potentially predictive relationship between vitamin D and preclinical dementia. Multiple confounders were considered to ensure a dementia-free sample.

Limitations

The majority of participants were Caucasian, which may limit generalizability. Repeat vitamin D levels were not available over time, and other factors like changes in lifestyle and diet that could influence vitamin D status during the long follow-up period were not fully accounted for.

Implications for Dementia Prevention

This study is among the first to examine the relationship between serum vitamin D levels and neuroimaging markers of preclinical dementia. Measuring vitamin D in early midlife offers an opportunity to potentially modify dementia risk.

The findings suggest that low vitamin D levels in midlife could be a modifiable factor to mitigate the risk of neuroimaging signs indicative of preclinical dementia.

However, as this was an observational study, it does not establish a causal relationship. Further longitudinal studies and randomized controlled trials are necessary to confirm if vitamin D has a preventive role in dementia.